艾弗森ballbet(中国)贝博

Be the most trusted biotech company

2026-03-20

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
2026-03-19

Henlius to Showcase Seven FIC/BIC Innovative Assets at AACR 2026, Highlighting Accelerated Early-Stage Innovation
2026-03-18

Henlius and SPH Join Forces in Strategic Partnership for a Healthier Future
2026-03-17

Henlius Debuts Preclinical Data of Its Proprietary CDH17 ADC, Showing a Differentiated Profile in GI Cancers at ADC Asia Congress 2026
2026-03-12

Henlius Initiates a Phase 2/3 MRCT of Its Pan-Tumor PD-L1 ADC HLX43 for sqNSCLC in the US
2026-03-09

Henlius Announces IND Approval for Its Proprietary Next Generation Tetra-Specific T-Cell Engager HLX3901
2026-03-09

IND Application for Potential First‑in‑Class B7‑H3–Targeting Sialidase Fusion Protein HLX316 Approved in China
2026-03-06

Results of Serplulimab in Lung Cancer Selected for ELCC 2026，continuously demonstrating its efficacy and potential
2026-03-05

Henlius Receives IND Approval for Its Potential BIC Novel Oral KAT6A/B Small Molecule Inhibitor HLX97